Marvel Biosciences receives Chinese patent for MB-204

Executive Summary

• Marvel Biosciences Corp. and its subsidiary Marvel Biotechnology Inc. have been granted a patent by the China National Intellectual Property Administration for their lead therapeutic candidate, MB-204.
• The patent (No. ZL202180020893.4) covers the composition of matter for MB-204, a novel fluorinated derivative of the adenosine A2A receptor antagonist Istradefylline.
• MB-204 has demonstrated strong preclinical efficacy in models for autism, Rett syndrome, and depression and is prepared to enter Phase 1 clinical trials.

Key Details

• Patent Details: Granted by the China National Intellectual Property Administration; Patent No. ZL202180020893.4; Title: "Purine Compounds for Treating Disorders."
• Asset Profile: MB-204 is a novel, fluorinated derivative of Istradefylline (an approved Parkinson's drug and the only adenosine A2A receptor blocker on the market).
• Key Attributes: Engineered for superior potency, longer duration, and improved tolerability compared to the parent compound.
• Preclinical Data: Demonstrated strong efficacy across multiple models for autism, Rett syndrome, and depression.
• Development Status: Ready to enter Phase 1 clinical trials.
• Target Indications: Autism, Rett syndrome, depression, Alzheimer's disease, and rare disorders such as fragile X syndrome.

Notable Quotes

• "This allowance further strengthens our global IP position in a key market," said J. Roderick Matheson, chief executive officer of Marvel Biosciences. "Securing these rights is an important step, and we look forward to achieving similar outcomes in other key jurisdictions. With approximately one in 36 children diagnosed with autism, there is a clear need for innovation. We remain committed to advancing MB-204 through the clinic to address these significant unmet medical needs."